Survey of drug therapy in type 2 diabetes mellitus (V). combined treatment with insulin plus an oral hypoglycemic agents: Clinical aspects and glycemie control (JDDM 19)

Journal of the Japan Diabetes Society

Volumn 53, Issue 10, 2010, Pages 737-744

  Kanatsuka, Azuma ^a   Kawai, Koichi ^b   Hirao, Koichi ^c   Oishi, Mariko ^d   Kobayashi, Masashi ^e  

^a Chiba Central Medical Center   (Japan)

^b Kawai Clinic   (Japan)

^c H E C Science Clinic   (Japan)

^d Oishi Clinic   (Japan)

^e UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649555260     PISSN: 0021437X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, Yamauchi M, Takagi H, Kawai K, Japan Diabetes Clinical Data Management Study Group (2006) The status of diabetes control and antidiabetic drug therapy in Japan-A cross sectional survey of 17,000 patients with diabetes mellitus (JDDMl). Diabetes Research and Clinical Practice 73:198-204
2. Sone H, Kawai K, Takagi H, Yamada N, Kobayashi M (2006) Outcome of one-year of specialist care of patients with type 2 diabetes: A multiple-cennter prospective survey (JDDM 2). Internal Medicine 45: 589-597
3. Kanatsuka K, Kawai K, Hirao H, Oishi M, Takagi H, Kobayashi M, Japan Diabetes Clinical Data Management Study Group (JDDM) (2006) Actual Usage and Clinical Effectiveness of Insulin Preparations in Patients with Type 1 Diabetes Mellitus in Japan: CoDiC̊-based Analysis of Clinical Data Obtained at Multiple Institutions (JDDM 3). Diabetes Research and Clinical Practice 72:277-283
4. Yokoyama H, Kawai K, Kobayashi M, Japan Diabetes Clinical Data Management Study Group (JDDM) (2007) Microalbuminuria is common in Japanese type 2 diabetic patients A nationwide survey from the Japan Diabetes Clinical Data Management Study Group QDDM 10). Diabetes Care 30:989-992
5. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tumori T, Berglund G, Altshuler D, Nilsson P, Groop L (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359: 2220-2232
6. Yokoyama H, Okudaira M, Otani T, Takaike H, Miura J. Saeki A. Uchigata Y, Omori Y (1997) Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care 20:844-847
7. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846
8. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
9. Zhou G. Myers R, Li Y, Chen Y, Shen X, FenyxMelody J, Wu M, Ventre J, Doebber T, Fuji N (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174
10. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B (2006) Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 29:1963-1972
11. Defronzo RA, Ferrannini E (1991) Insulin resistance. A multifaced syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194